Comparison of the antipsoriatic effect and tolerability of calcipotriol-containing products in the treatment of psoriasis vulgaris using a modified psoriasis plaque test

Clinical Drug Investigation

Volumn 32, Issue 9, 2012, Pages 613-619

  Queille Roussel, Catherine ^a   Hoffmann, Vibeke ^b   Ganslandt, Cecilia ^b   Hansen, Klaus Krog ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b LEO PHARMA A S   (Denmark)

Author keywords

betamethasone dipropionate; calcipotriol; plaque psoriasis; psoriasis

Indexed keywords

ANTIPSORIASIS AGENT; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CALCIPOTRIOL PLUS HYDROCORTISONE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SKINFOLD THICKNESS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; CALCITRIOL; DOSAGE FORMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PSORIASIS;

EID: 84865126644     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11634710-000000000-00000     Document Type: Article

References (13)

1. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370 (9583): 263-71
2. Dumas KJ, Scholtz JR. The psoriasis bio-assay for topical corticosteroid activity. Acta Derm Venereol 1972; 52 (1): 43-8
3. Katz M, Shaikh Z, Maibach HI. Scholtz-Dumas psoriasis small plaque bioassay. J Dermatol Treat 2000; 11 (1): 15-9 (Pubitemid 30171145)
4. Kvist PH, Svensson L, Hagberg O, et al. Comparison of the effects of vitamin D products in a psoriasis plaque test and amurine psoriasis xenograftmodel. J Transl Med 2009; 7: 107
5. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of oncedaily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150 (6): 1167-73 (Pubitemid 38932288)
6. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147 (2): 316-23
7. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205 (4): 389-93 (Pubitemid 35356768)
8. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20 (4): 465-71
9. Langley RG, Gupta A, Papp K, et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomised, controlled clinical trial. Dermatology 2011; 222 (2): 148-56
10. Ortonne JP, Noerrelund KL, Papp K, et al. Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body. Eur J Dermatol 2010; 20 (5): 585-9
11. Zivkovich AH, Feldman SR. Are ointments better than other vehicles for corticosteroid treatment of psoriasis? J Drugs Dermatol 2009; 8 (6): 570-2
12. Hol K. European study into the opinions of psoriasis patients and physicians. 19th Congress of the European Academy of Dermatology and Venereology (EADV), 6-10 October 2010, Gothenburg, Sweden; p. 573
13. Hol K. Patient preference for topical psoriasis formulations. 19th Congress of the European Academy of Dermatology and Venereology (EADV), 6-10 October 2010, Gothenburg, Sweden; p. 572